145 related articles for article (PubMed ID: 37225364)
1. The Inflation Reduction Act and Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Disease.
Kazi DS; DeJong C; Chen R; Wadhera RK; Tseng CW
J Am Coll Cardiol; 2023 May; 81(21):2103-2111. PubMed ID: 37225364
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019.
Zhou T; Liu P; Dhruva SS; Shah ND; Ramachandran R; Berg KM; Ross JS
JAMA Intern Med; 2022 Feb; 182(2):185-195. PubMed ID: 34982097
[TBL] [Abstract][Full Text] [Related]
3. Out-of-Pocket Drug Costs for Medicare Beneficiaries With Cardiovascular Risk Factors Under the Inflation Reduction Act.
Narasimmaraj PR; Oseran A; Tale A; Xu J; Essien UR; Kazi DS; Yeh RW; Wadhera RK
J Am Coll Cardiol; 2023 Apr; 81(15):1491-1501. PubMed ID: 37045519
[TBL] [Abstract][Full Text] [Related]
4. The Inflation Reduction Act: How Will Medicare Negotiating Drug Prices Impact Patients with Heart Disease?
Johnson M; Kishore S; Nayak RK; Dusetzina SB
Curr Cardiol Rep; 2023 Jun; 25(6):577-581. PubMed ID: 37097432
[TBL] [Abstract][Full Text] [Related]
5. Out-of-pocket payments for part d covered medications by medicare fee-for-service beneficiaries with heart failure with reduced ejection fraction.
Fendrick AM; Djatche L; Pulungan Z; Teigland C; Yang M; Lautsch D; Hilkert R; Mentz R
Am Heart J; 2022 Apr; 246():74-81. PubMed ID: 34774543
[TBL] [Abstract][Full Text] [Related]
6. Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer.
Cortese BD; Dusetzina SB; Al Hussein Al Awamlh B; Penson DF; Chang SS; Barocas DA; Luckenbaugh AN; Scarpato KR; Moses KA; Talwar R
Urol Pract; 2023 Sep; 10(5):476-483. PubMed ID: 37409930
[TBL] [Abstract][Full Text] [Related]
7. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure.
Faridi KF; Dayoub EJ; Ross JS; Dhruva SS; Ahmad T; Desai NR
J Am Coll Cardiol; 2022 Jun; 79(25):2516-2525. PubMed ID: 35738713
[TBL] [Abstract][Full Text] [Related]
8. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase.
Trish E; Xu J; Joyce G
Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634
[TBL] [Abstract][Full Text] [Related]
9. Estimation of Out-of-Pocket Costs for Guideline-Directed Medical Therapy for Heart Failure Under Medicare Part D and the Inflation Reduction Act.
Johnson M; Nayak RK; Gilstrap L; Dusetzina SB
JAMA Cardiol; 2023 Mar; 8(3):299-301. PubMed ID: 36630145
[TBL] [Abstract][Full Text] [Related]
10. Federal and Individual Spending on the 10 Costliest Medications in Medicare Part D from 2011 to 2015.
Watanabe JH; Chau DL; Hirsch JD
J Am Geriatr Soc; 2018 Aug; 66(8):1621-1624. PubMed ID: 29972589
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Medicare Part D on the Proportion of Out-of-Pocket Prescription Drug Costs Among Older Adults With Diabetes.
Choi YJ; Jia H; Gross T; Weinger K; Stone PW; Smaldone AM
Diabetes Care; 2017 Apr; 40(4):502-508. PubMed ID: 27803119
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Expected Out-of-Pocket Spending for Rheumatoid Arthritis Biologics Among Patients Enrolled in Medicare Part D, 2010-2019.
Erath A; Dusetzina SB
JAMA Netw Open; 2020 Apr; 3(4):e203969. PubMed ID: 32338754
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance.
DiStefano MJ; Kang SY; Parasrampuria S; Anderson GF
JAMA Health Forum; 2023 May; 4(5):e231090. PubMed ID: 37234016
[TBL] [Abstract][Full Text] [Related]
14. Five-year impact of Medicare Part D coverage gap reform on drug expenditures and utilization.
Park J; Look KA
Health Serv Res; 2022 Feb; 57(1):56-65. PubMed ID: 33870486
[TBL] [Abstract][Full Text] [Related]
15. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
16. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
Tseng CW; Brook RH; Keeler E; Mangione CM
JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
[TBL] [Abstract][Full Text] [Related]
17. Prescription drug spending and hospital use among Medicare beneficiaries with heart failure.
McGee BT; Higgins MK; Phillips V; Butler J
Res Social Adm Pharm; 2020 Oct; 16(10):1452-1458. PubMed ID: 31953113
[TBL] [Abstract][Full Text] [Related]
18. Low Utilization of Beta-Blockers Among Medicare Beneficiaries Hospitalized for Heart Failure With Reduced Ejection Fraction.
Loop MS; van Dyke MK; Chen L; Safford MM; Kilgore ML; Brown TM; Durant RW; Levitan EB
J Card Fail; 2019 May; 25(5):343-351. PubMed ID: 30339796
[TBL] [Abstract][Full Text] [Related]
19. Use and Out-of-Pocket Cost of Sacubitril-Valsartan in Patients With Heart Failure.
Shore S; Basu T; Kamdar N; Brady P; Birati E; Hummel SL; Chopra V; Nallamothu BK
J Am Heart Assoc; 2022 Sep; 11(17):e023950. PubMed ID: 36000415
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Proposed Medicare Part B to Part D Shift With Associated Changes in Total Spending and Patient Cost-Sharing for Prescription Drugs.
Hwang TJ; Jain N; Lauffenburger JC; Vokinger KN; Kesselheim AS
JAMA Intern Med; 2019 Mar; 179(3):374-380. PubMed ID: 30640379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
